Business Description
ISIN : US9553061055
Share Class Description:
WST: Ordinary SharesTotal Employee Number:
10,800Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.4 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.36 | |||||
Interest Coverage | 160.58 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 17.07 | |||||
Beneish M-Score | -2.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.5 | |||||
3-Year EBITDA Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | -5.3 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.59 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.39 | |||||
9-Day RSI | 58.81 | |||||
14-Day RSI | 56.18 | |||||
3-1 Month Momentum % | 15.33 | |||||
6-1 Month Momentum % | 46.12 | |||||
12-1 Month Momentum % | 43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 2.12 | |||||
Cash Ratio | 0.68 | |||||
Days Inventory | 76.47 | |||||
Days Sales Outstanding | 69.77 | |||||
Days Payable | 43.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.25 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | 5.2 | |||||
Forward Dividend Yield % | 0.25 | |||||
5-Year Yield-on-Cost % | 0.33 | |||||
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 2.06 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.79 | |||||
Operating Margin % | 21.72 | |||||
Net Margin % | 16.98 | |||||
EBITDA Margin % | 26.44 | |||||
FCF Margin % | 13.13 | |||||
OCF Margin % | 19.91 | |||||
ROE % | 18.66 | |||||
ROA % | 13.77 | |||||
ROIC % | 18.52 | |||||
3-Year ROIIC % | -19.72 | |||||
ROC (Joel Greenblatt) % | 28.52 | |||||
ROCE % | 20.17 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.21 | |||||
Forward PE Ratio | 39.44 | |||||
PE Ratio without NRI | 41.54 | |||||
Shiller PE Ratio | 53.66 | |||||
Price-to-Owner-Earnings | 67.54 | |||||
PEG Ratio | 7.69 | |||||
PS Ratio | 7.68 | |||||
PB Ratio | 8.31 | |||||
Price-to-Tangible-Book | 8.65 | |||||
Price-to-Free-Cash-Flow | 58.48 | |||||
Price-to-Operating-Cash-Flow | 38.57 | |||||
EV-to-EBIT | 35.42 | |||||
EV-to-Forward-EBIT | 33.43 | |||||
EV-to-EBITDA | 28.11 | |||||
EV-to-Forward-EBITDA | 26.22 | |||||
EV-to-Revenue | 7.43 | |||||
EV-to-Forward-Revenue | 7.35 | |||||
EV-to-FCF | 56.59 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 3.93 | |||||
Price-to-DCF (Earnings Based) | 1.56 | |||||
Price-to-DCF (FCF Based) | 1.87 | |||||
Price-to-Median-PS-Value | 1.15 | |||||
Price-to-Graham-Number | 4 | |||||
| Price-to-Net-Current-Asset-Value | 34.45 | |||||
Earnings Yield (Greenblatt) % | 2.82 | |||||
FCF Yield % | 1.76 | |||||
Forward Rate of Return (Yacktman) % | 1.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:WST
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
West Pharmaceutical Services Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,326.8 | ||
| EPS (TTM) ($) | 7.81 | ||
| Beta | 1.0648 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 31.39 | ||
| 14-Day RSI | 56.18 | ||
| 14-Day ATR ($) | 8.509324 | ||
| 20-Day SMA ($) | 345.799 | ||
| 12-1 Month Momentum % | 43 | ||
| 52-Week Range ($) | 223.83 - 386 | ||
| Shares Outstanding (Mil) | 70.38 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
West Pharmaceutical Services Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
West Pharmaceutical Services Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-17 | In 180 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-12 08:00 | In 176 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 175 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-23 08:00 | In 64 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 | In 63 days | ||
| USD 0.220000 Cash Dividend | 2026-07-29 | 337.00 (+0.73%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 08:00 | 358.41 (+0.32%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 358.41 (+0.32%) | ||
| William Blair Annual Growth Stock Conference | 2026-06-02 16:00 | 316.30 (-1.66%) | ||
| Bank of America Global Healthcare Conference | 2026-05-20 14:20 | 303.93 (-0.15%) |
West Pharmaceutical Services Inc Frequently Asked Questions
Guru Commentaries on NYSE:WST
Our investment case for West Pharmaceutical Services is clear: West sits in a uniquely strong position within a structurally growing industry, with the potential to create huge sustainability gains for the world. We believe that there are substantial barriers in the way of competitors who would encroach on West’s business. The first relates to economics. Because a stopper is so cheap, customers have little incentive even to consider the products of other suppliers. We believe that West is likely to benefit from two big tailwinds in the coming years. The first is regulation. Europe’s Annex 1 rules, tightened in 2023, demand far ‘cleaner’ packaging products. High-performing companies like West are likely to be the biggest beneficiaries of these regulatory shifts. At current prices, we think the company represents a tremendous opportunity.
West Pharmaceutical is a leading provider of injectable drug packaging solutions. The company delivered a strong quarter, with revenue and earnings exceeding expectations, driven by accelerating demand for high-value products and GLP-1 components. Margin expansion improved as the mix shifted toward higher margin offerings, and management raised full-year guidance, reflecting better operating execution and easing capacity constraints. Recent results highlight continued strength in both GLP-1 and non-GLP-1 components, indicating robust demand and a positive outlook for the business.
Press Release
Articles on West Pharmaceutical Services Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
